Skip to main content

Evommune, Inc 10-Q for FY2026 Q3

Evommune, Inc. (EVMN)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

Evommune, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Evommune discontinued EVO756 development in CSU and AD after Phase 2b trials missed endpoints, while migraine development continues. It reported $262.3 million in liquidity and expects funding into the second half of 2029. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$0
compared with $10M a year earlier
Net loss
$30.88M
compared with a net loss of $12.48M a year earlier
Diluted EPS
-$0.85
compared with -$8.07 a year earlier